World’s first malaria vaccine may hit markets by 2015
The world’s first anti-malaria vaccine may be approved for use within two years
UK drug maker GlaxoSmithKline (GSK) is seeking regulatory approval for the vaccine after trial data showed that it had cut the number of cases in African children. Results from a large-scale Phase III trial, presented in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 months after vaccination.
“Based on these data, GSK now intends to submit a regulatory application to the European Medicines Agency (EMA),” GSK said in a statement.
The World Health Organization (WHO) has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible as early as 2015 if it is granted a positive scientific opinion by EMA, it said.
These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases in young children (aged 5-17 months at first vaccination) and to reduce by around a quarter the malaria cases in infants (aged 6-12 weeks at first vaccination).
Vaccine efficacy was also assessed separately at each of the trial sites, which represent a wide range of malaria transmission settings; efficacy was found to be statistically significant at all sites in young children and at four sites in infants, according to the statement.
Eleven African research centers in seven African countries are conducting this trial, together with GSK and the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill & Melinda Gates Foundation to MVI.
If the EMA gives a positive opinion, and the public health information is satisfactory, including safety and efficacy data from the Phase III program, the WHO has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible as early as 2015, GSK said in a statement.